PIKing up and AKTing on resistance mutations in osimertinib-treated EGFR-mutated NSCLC.
Natalie I VokesXiuning LiTimothy Anthony YapPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
A recent study identified high rates of PI3K-AKT pathway mutations from the FLAURA and AURA3 osimertinib trials and pre-clinically validated that these mutations decreased osimertinib sensitivity in EGFR-mutated NSCLC. The AKT inhibitor capivasertib was found to overcome this resistance, providing important rationale for the development of AKT inhibitors in NSCLC.